Effectdossier · gearchiveerd kwartaal
ZVRA
Zevra Therapeutics, Inc. · Healthcare · Biotechnology
16Gevolgde houders
+2Δ houders
19.14MGehouden aandelen
$181.99MGerapporteerde waarde
+2Nieuwe posities
−0Uitstappen
Momentum-inputs (vergelijkbare managers):
breedte van houders +14.3% ·
aandelenstroom -0.8% ·
netto nieuwe posities +12.5%
— formule
Versnippering van eigendom — meer houders, kleinere totale positie
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
Eigendom in de tijd
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | +6 | 29.05M | $415.89M | +12 | −6 |
| Q1 2026 | 69 | 0 | 26.10M | $242.75M | +4 | −4 |
| Q4 2025 | 68 | +1 | 25.36M | $227.23M | +1 | — |
| Q3 2025 | 16 | +2 | 19.14M | $181.99M | +2 | — |
| Q2 2025 | 11 | 0 | 17.09M | $150.53M | — | — |
| Q1 2025 | 8 | 0 | 6.58M | $49.25M | +1 | −1 |
| Q4 2024 | 8 | +1 | 6.30M | $52.58M | +2 | −1 |
| Q3 2024 | 6 | +2 | 1.92M | $13.36M | +3 | −1 |
| Q2 2024 | 4 | — | 1.15M | $5.62M | — | — |
Wie het bezit · Q3 2025
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | BlackRock ✦ (passief) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | BlackRock ✦ (passief) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | BlackRock ✦ (passief) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | BlackRock ✦ (passief) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | BlackRock ✦ (passief) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | BlackRock ✦ (passief) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | BlackRock ✦ (passief) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | The Vanguard Group ✦ (passief) | 3.08M | +4.4% | $29.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | The Vanguard Group ✦ (passief) | 3.08M | +4.4% | $29.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | The Vanguard Group ✦ (passief) | 3.08M | +4.4% | $29.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 2.23M | -46.6% | $21.16M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 1.63M | -28.6% | $15.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Fidelity (FMR) ✦ | 1.63M | -28.6% | $15.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 1.63M | -28.6% | $15.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Fidelity (FMR) ✦ | 1.63M | -28.6% | $15.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (passief) | 1.43M | +14.9% | $13.57M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Geode Capital Management ✦ (passief) | 1.30M | +4.7% | $12.37M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Geode Capital Management ✦ (passief) | 1.30M | +4.7% | $12.37M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | Millennium Management ✦ | 1.04M | +63.1% | $9.85M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 21 | Marshall Wace ✦ | 912.30K | Nieuw | $8.68M | 0.0% | New | 1 | SEC ↗ |
| 22 | Marshall Wace ✦ | 912.30K | Nieuw | $8.68M | 0.0% | New | 1 | SEC ↗ |
| 23 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Goldman Sachs Group ✦ | 761.78K | — | $7.24M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Goldman Sachs Group ✦ | 761.78K | — | $7.24M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | D. E. Shaw & Co. ✦ | 725.83K | +283.4% | $6.90M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 32 | D. E. Shaw & Co. ✦ | 725.83K | +283.4% | $6.90M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 33 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 34 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 35 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 36 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 37 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 38 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 39 | Citadel Advisors ✦ | 191.80K | +67.8% | $1.82M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 40 | Wellington Management ✦ | 187.27K | +28.0% | $1.78M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 41 | Wellington Management ✦ | 187.27K | +28.0% | $1.78M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 42 | Wellington Management ✦ | 187.27K | +28.0% | $1.78M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 43 | AQR Capital Management ✦ | 152.31K | Nieuw | $1.45M | 0.0% | New | 1 | SEC ↗ |
| 44 | AQR Capital Management ✦ | 152.31K | Nieuw | $1.45M | 0.0% | New | 1 | SEC ↗ |
| 45 | AQR Capital Management ✦ | 152.31K | Nieuw | $1.45M | 0.0% | New | 1 | SEC ↗ |
| 46 | AQR Capital Management ✦ | 152.31K | Nieuw | $1.45M | 0.0% | New | 1 | SEC ↗ |
| 47 | T. Rowe Price ✦ | 28.49K | +10.9% | $271,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Marshall Wace | $8.68M | 0.0% |
| Marshall Wace | $8.68M | 0.0% |
| AQR Capital Management | $1.45M | 0.0% |
| AQR Capital Management | $1.45M | 0.0% |
| AQR Capital Management | $1.45M | 0.0% |
| AQR Capital Management | $1.45M | 0.0% |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 147 houders, 40.93M aandelen, $378.34M gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Vaak gezamenlijk in bezit
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR.
Rapportageperiode: Q3 2025 ·
Methodologie ·
Verkrijg dit via de API